{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022277","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.313698+00:00","generated_at":"2026-05-16T20:14:28.683398+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"DARE Bioscience reports Q3 cash $23.1M; Sildenafil Cream on track for Dec launch via 503B","bullets":["Cash and equivalents $23.1M; working capital $3.8M as of Sep 30, 2025.","R&D expense $1.2M (down 56% YoY) due to grant funding; G&A $2.5M (up 25% YoY) on commercial readiness.","DARE to PLAY Sildenafil Cream on track for initial Rx fulfillment Dec 2025 via 503B compounding (near-term revenue).","Positive DSMB recommendation for Ovaprene Phase 3 study; enrollment continues.","Received $6M (Jul) and $4M (Oct) grant installments for DARE-LARC1; $3.6M expected for DARE-NHC in Nov 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022277","json":"https://secwatch.observer/filing/0001493152-25-022277.json","markdown":"https://secwatch.observer/filing/0001493152-25-022277.md","text":"https://secwatch.observer/filing/0001493152-25-022277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315225022277/0001493152-25-022277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315225022277/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:14:28.683398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}